GBS Management Algorithm
Intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days is the first-line treatment for adult patients with Guillain-Barré syndrome who cannot walk independently, initiated within 2 weeks of weakness onset. 1
Step 1: Confirm Diagnosis
Look for rapidly progressive bilateral limb weakness (typically ascending from legs to arms) with:
- Areflexia or hyporeflexia (present in almost all patients at nadir)
- Progression to maximum disability within 2-4 weeks (if >4 weeks, consider chronic inflammatory demyelinating polyneuropathy)
- Preceding infection (diarrhea or respiratory illness in preceding 1-4 weeks)
- CSF albuminocytologic dissociation (elevated protein with normal cell count)
- Electrodiagnostic studies to support diagnosis and exclude mimics 1
Critical pitfall: In children <6 years, presentation may be atypical with nonspecific pain, refusal to walk, or irritability rather than classic ascending weakness. 1
Step 2: Assess Disease Severity & ICU Admission Criteria
Admit to ICU immediately if any of the following:
- Respiratory distress (inability to count to 15 in one breath, accessory muscle use, vital capacity <15-20 ml/kg)
- Severe bulbar dysfunction (impaired swallowing, diminished cough)
- Severe autonomic instability (arrhythmias, marked blood pressure fluctuations)
- Rapid progression of weakness 1
Use EGRIS score to predict mechanical ventilation risk within 1 week:
- Days to admission: ≤3 days (2 points), 4-7 days (1 point)
- Facial/bulbar weakness present (1 point)
- MRC sum score: ≤20 (4 points), 21-30 (3 points), 31-40 (2 points), 41-50 (1 point) 1
Step 3: Initiate Immunotherapy
Treatment algorithm:
For patients unable to walk independently (GBS disability score ≥3):
Within 2 weeks of weakness onset:
- First choice: IVIg 0.4 g/kg/day for 5 consecutive days (easier to administer, more widely available) 1, 2
- Alternative: Plasma exchange 200-250 ml/kg over 5 sessions in 1-2 weeks (equally effective but requires specialized equipment) 1
Between 2-4 weeks of onset:
Beyond 4 weeks:
- Plasma exchange may still be considered if within 4 weeks of onset 2
Special populations:
Pregnant women: IVIg preferred over plasma exchange (both safe, but IVIg requires less monitoring) 1
Children: IVIg 0.4 g/kg/day for 5 days (NOT 2-day regimen—higher treatment-related fluctuation rate of 22% vs 0%) 1
Miller Fisher Syndrome (pure): Observation without treatment acceptable (most recover completely within 6 months), but monitor closely for progression to limb weakness or respiratory failure 1
What NOT to do:
- Do NOT use corticosteroids (oral corticosteroids worsen outcome; IV corticosteroids not beneficial) 1, 2
- Do NOT combine plasma exchange followed by IVIg (no additional benefit) 1
- Do NOT give second IVIg course for poor prognosis (no evidence of benefit) 2
Step 4: Monitor Disease Progression
Respiratory monitoring (frequency based on severity):
- Vital capacity measurements
- "20/30/40 rule": Risk of respiratory failure if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1
- Single breath count ≤19 predicts need for mechanical ventilation 1
Neurological monitoring:
- MRC sum score for muscle strength
- GBS disability scale for functional status
- Swallowing and cough assessment
- Autonomic function (ECG, heart rate, blood pressure, bowel/bladder) 1
Critical pitfall: Two-thirds of GBS deaths occur during recovery phase from cardiovascular/respiratory complications—maintain vigilance even after ICU discharge. 1
Step 5: Manage Treatment-Related Fluctuations (TRFs)
If deterioration occurs within 2 months after initial improvement:
- This represents treatment-related fluctuation (6-10% of patients) 1
- Consider repeating IVIg or switching to plasma exchange (though no strong evidence for benefit) 1
- Distinguish from insufficient initial response (40% don't improve in first 4 weeks—this does NOT indicate treatment failure) 1
Step 6: Predict Outcome
Use modified Erasmus GBS Outcome Score (mEGOS) at admission to predict inability to walk independently at 6 months 1, 2
Key prognostic factors:
- Age >60 years
- Preceding diarrheal illness
- Severe weakness at nadir (MRC sum score)
- Axonal subtype on nerve conduction studies
Recovery timeline: Improvement can continue beyond 3 years; recurrence is rare (2-5%) 1
Step 7: Manage Complications
Pain management (present in majority):
- Weakly recommend: Gabapentinoids, tricyclic antidepressants, or carbamazepine 2
Standard ICU complications:
- DVT prophylaxis
- Pressure ulcer prevention
- Hospital-acquired infection prevention
- Corneal protection in facial palsy
- Contracture prevention 1
Autonomic dysfunction: Monitor and treat arrhythmias, blood pressure instability
Psychological support: Patients maintain full consciousness—explain procedures, address anxiety/depression early 1
This algorithm prioritizes mortality and morbidity reduction through early recognition, appropriate ICU triage, timely immunotherapy, and vigilant monitoring for life-threatening complications.